Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 1;29(12):2879–2889. doi: 10.1681/ASN.2018070740

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 by the American Society of Nephrology

PMC Copyright notice

Figure 4. — Dose increase results in antibody saturation but may also trigger further ADA formation. (A) Saturation of ADAs due to dose increase. (B) Short-term effect of dose increase due to switch of product. (C) Effect of dose increase due to stepwise escalation/product switch (396th infusion). (D) Long-term effect of dose increase due to product switch (260th infusion) resulted in increased ADA titers, but titers could be saturated. (E) Long-term effect of dose increase due to product switch (185th infusion) resulted in stable ADA titers, which could be saturated. Green bars indicate saturation (agalsidase excess), red bars indicate no saturation (antibody excess) during infusion. Dotted lines represent plasma lyso-Gb3 levels.